Human TNFR1 / CD120a / TNFRSF1A Protein, His Tag
分子別名(Synonym)
TNFR1,CD120a,TNFRSF1A,FPF,TBP1,TNF-R,TNF-R-I,TNF-R55,TNFAR,TNFR55,TNFR60,p55,p60
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human TNFR1, His Tag (TN1-H5222) is expressed from human 293 cells (HEK293). It contains AA Ile 22 - Thr 211 (Accession # NP_001056).
Predicted N-terminus: Ile 22
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 22.3 kDa. The protein migrates as 28-40 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to different glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>90% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
TNFR1也稱為TNFRSF1A,屬于TNF受體超家族。TNFR1包含一個(gè)死亡結(jié)構(gòu)域和四個(gè)TNFR-Cys重復(fù)序列。TNF-R1是TNFSF2/TNFα和同源三聚體TNFSF1/淋巴毒素-α的受體。銜接分子FADD將胱天蛋白酶-8募集到活化的受體上。由此產(chǎn)生的死亡誘導(dǎo)信號(hào)復(fù)合物(DISC)進(jìn)行胱天蛋白酶-8蛋白水解激活,啟動(dòng)隨后介導(dǎo)凋亡的胱天蛋白酶(天冬氨酸特異性半胱氨酸蛋白酶)級(jí)聯(lián)反應(yīng)。TNFR1有助于誘導(dǎo)非細(xì)胞殺傷性TNF效應(yīng),包括抗病毒狀態(tài)和酸性鞘磷脂酶的激活。TNFRSF1A的缺陷是家族性冬眠熱(FHF)的原因。
關(guān)鍵字: TNFR1;TNFR1蛋白;TNFR1重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。